文献速递垂体与肾上腺疾病

原发性和继发性肾上腺功能不全患者的心血管疾病及合并症的作用

Cardiovascular Disease in Patients With Primary and Secondary Adrenal Insufficiency and the Role of Comorbidities.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

调整合并症后复合心血管事件风险增加不再显著,但继发性患者脑血管事件独立增加且与颅照射相关;原发与继发性患者缺血性心脏病死亡风险仍升高。

要点

  • 肾上腺功能不全患者复合心血管事件粗风险升高,但调整合并症后基本消失。
  • 继发性肾上腺功能不全患者脑血管事件独立增加,且与颅照射治疗相关。
  • 调整合并症后,原发与继发性患者缺血性心脏病死亡风险仍分别升高。

核心结论

  • 合并症在很大程度上解释了肾上腺功能不全患者心血管事件增加,但继发性患者脑血管事件独立增加且与照射治疗相关。
  • 原发性和继发性肾上腺功能不全患者调整合并症后心血管死亡风险仍增加。

研究设计与样本

  • 回顾性队列研究,使用英国全科医生数据库CPRD。
  • 分析时对合并症(糖尿病、高血压、血脂异常、既往心血管病、吸烟)进行调整。
  • 主要结局为CPRD记录的复合心血管事件及链接国家死亡数据的心血管死亡。

主要发现

  • 任何原因肾上腺功能不全患者复合心血管事件的未调整HR为1.28(95%CI 1.20-1.36),调整后为1.07(95%CI 1.01-1.14)。
  • 继发性肾上腺功能不全患者脑血管事件调整后HR为1.53(95%CI 1.34-1.74),与颅照射治疗相关。
  • 原发性肾上腺功能不全缺血性心脏病死亡调整后HR为1.86(95%CI 1.25-2.78),继发性为1.39(95%CI 1.02-1.89)。

临床怎么用

  • 对肾上腺功能不全患者应积极管理糖尿病、高血压、血脂异常和吸烟等合并症。
  • 继发性肾上腺功能不全患者需关注脑血管事件风险,尤其有颅照射治疗史者。
  • 原发与继发性患者均需关注缺血性心脏病死亡风险,即使调整合并症后仍升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Mortality studies have established that cardiovascular disease is the leading cause of death in patients with adrenal insufficiency and the risk is greater than that observed in individually matched controls. OBJECTIVE: Here we have performed a detailed analysis of cardiovascular morbidity and mortality, taking account of the role of comorbidities. METHODS: We performed a retrospective cohort study using the Clinical Practice Research Datalink (CPRD), a UK general practitioner database. The participant population comprised 6821 patients with adrenal insufficiency (primary, 2052; secondary, 3948) compared with 67 564 individually matched controls, with and without adjustment for comorbidities (diabetes, hypertension, dyslipidemia, previous cardiovascular disease, and smoking). The main outcome measures were composite cardiovascular events recorded in the CPRD and cardiovascular mortality in participants with linked national mortality data. RESULTS: Hazard ratios (95% CI) for composite cardiovascular events in patients with adrenal insufficiency of any cause were 1.28 (1.20-1.36, unadjusted) and 1.07 (1.01-1.14, adjusted). Increased cerebrovascular events in patients with secondary adrenal insufficiency accounted for most of the increased hazard (1.53 [1.34-1.74, adjusted]) and were associated with cranial irradiation therapy. Cardiovascular mortality data were available for 3547 patients and 34 944 controls. The adjusted hazard ratio for ischemic heart disease mortality was 1.86 (1.25-2.78) for primary adrenal insufficiency and 1.39 (1.02-1.89) for secondary. CONCLUSION: Comorbidities largely accounted for the increased cardiovascular events but in secondary adrenal insufficiency, cerebrovascular events were independently increased and associated with irradiation treatment. However, the risk of cardiovascular mortality remained increased even following adjustment for comorbidities in both primary and secondary adrenal insufficiency.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ngaosuwan K, Johnston DG, Godsland IF, et al. Cardiovascular Disease in Patients With Primary and Secondary Adrenal Insufficiency and the Role of Comorbidities. J Clin Endocrinol Metab. 2021. PMID: 33585930. doi:10.1210/clinem/dgab063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。